XML 58 R34.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Note 4 - Investment in Wanchun Pharma (Details Textual) $ / shares in Units, ¥ in Thousands |  |  | 1 Months Ended | 3 Months Ended |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jul. 20, 2015 USD ($) $ / shares shares | Jul. 20, 2015 CNY (¥) shares | Mar. 30, 2015 USD ($) | Mar. 30, 2015 CNY (¥) | Dec. 31, 2014 USD ($) | Dec. 31, 2014 CNY (¥) | Dec. 31, 2012 USD ($) | Dec. 31, 2012 CNY (¥) | Jul. 20, 2015 USD ($) $ / shares shares | Apr. 14, 2015 USD ($) | Dec. 31, 2016 USD ($) | Dec. 31, 2015 USD ($) | Jul. 02, 2015 | Apr. 10, 2015 | Dec. 31, 2014 CNY (¥)
Assets |  |  |  |  |  |  |  |  |  |  | $ 14,908,000 | $ 10,970,000 |  |  |
Cash |  |  |  |  |  |  |  |  |  |  | $ 11,687,000 | $ 10,821,000 |  |  |
Wanchun Pharma [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Equity Method Investments | $ 2,400,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity Method Investments |  |  |  |  | $ (196,000) |  |  |  |  |  |  |  |  |  |
Receivables, Fair Value Disclosure |  |  |  |  | 960,000 |  |  |  |  |  |  |  |  |  |
Investment Liability, Equity Method investment | 239,000 |  |  |  | 196,000 |  |  |  | $ 239,000 |  |  |  |  |  |
Assets | $ 1,347,000 |  |  |  |  |  |  |  | 1,347,000 |  |  |  |  |  |
Equity Method Investment, Summarized Financial Information, Net Income (Loss) |  |  |  |  |  |  |  |  | 49,000 | $ 48,000 |  |  |  |  |
Equity Method Investment, Summarized Financial Information, Revenue |  |  |  |  |  |  |  |  | $ 0 | $ 0 |  |  |  |  |
Wanchun Biotech [Member] | Wanchun Pharma [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Equity Method Investments |  |  | $ 1,611,000 | ¥ 10,000 | 3,212,000 | ¥ 20,000 |  |  |  |  |  |  |  |  |
Equity Method Investment, Ownership Percentage | 9.09% |  | 9.09% | 9.09% |  |  | 90.91% | 90.91% | 9.09% |  |  |  | 100.00% | 9.09% |
Wanchun Biotech [Member] | Wanchun Pharma [Member] | Patents [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Equity Method Investments |  |  |  |  |  |  | $ 16,042,000 | ¥ 100,000 |  |  |  |  |  |  |
Shanghai Fosun [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Equity Method Investments | $ 1,611,000 | ¥ 10,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Equity Method Investments, Shares | shares | 240,000 | 240,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Shanghai Fosun [Member] | Wanchun Pharma [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Equity Method Investments |  |  |  |  | 3,212,000 | ¥ 20,000 | $ 1,604,000 | ¥ 10,000 |  |  |  |  |  |  |
Equity Method Investment, Ownership Percentage |  |  |  |  |  |  | 9.09% | 9.09% |  |  |  |  |  |  |
Shanghai Fosun [Member] | Wanchun Pharma [Member] | Option to Transfer Capital Contribution Obligation to Wanchun Biotech [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contractual Obligation |  |  |  |  | $ 3,212,000 |  |  |  |  |  |  |  |  |  | ¥ 20,000
Fosun Hong Kong [Member] | BeyondSpring [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Equity Method Investments | $ 1,611,000 | ¥ 10,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Equity Method Investments, Shares | shares | 240,000 | 240,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Number of Shares, Used in Fair Value Measurement | shares | 240,000 |  |  |  |  |  |  |  | 240,000 |  |  |  |  |  |
Share Price | $ / shares | $ 10 |  |  |  |  |  |  |  | $ 10 |  |  |  |  |  |
Shares Used in Fair Value Measurement, Value | $ 2,400,000 |  |  |  |  |  |  |  | $ 2,400,000 |  |  |  |  |  |
Wanchun Pharma [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Assets | 1,347,000 |  |  |  |  |  |  |  | 1,347,000 |  |  |  |  |  |
Cash | $ 1,256 |  |  |  |  |  |  |  | $ 1,256 |  |  |  |  |  |

X
- Definition The liability associated with the holding of certain equity method investments. + References No definition available. + Details
Name: | bysi_InvestmentLiabilityEquityMethodInvestment
Namespace Prefix: | bysi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The number of shares whose fair value has been evaluated pursuant to certain purchases. + References No definition available. + Details
Name: | bysi_NumberOfSharesUsedInFairValueMeasurement
Namespace Prefix: | bysi_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The shares associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + References No definition available. + Details
Name: | bysi_PaymentsToAcquireEquityMethodInvestmentsShares
Namespace Prefix: | bysi_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The fair value of shares that have been measured pursuant to certain stock purchases. + References No definition available. + Details
Name: | bysi_SharesUsedInFairValueMeasurementValue
Namespace Prefix: | bysi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 + Details
Name: | us-gaap_Assets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_Cash
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments. + References No definition available. + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of net income (loss) reported by an equity method investment of the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33912-111571 + Details
Name: | us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of revenue from sale of goods and services reduced by sales returns, allowances, and discounts reported by an equity method investment of the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=66022249&loc=d3e33749-111570 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_EquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair value portion of receivables, including, but not limited to, trade account receivables, note receivables, and loan receivables. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(7)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-02(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13728-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_ReceivablesFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bysi_WanchunPharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=bysi_WanchunBiotechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=bysi_ShanghaiFosunMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bysi_OptionToTransferCapitalContributionObligationToWanchunBiotechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=bysi_FosunHongKongMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bysi_BeyondSpringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=bysi_WanchunPharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |